Rezdiffra (Resmetirom) Adolescent (12 to 17) Safety: What Clinicians and Families Need to Know

Why Adolescent MASH Is a Clinical Priority

Metabolic dysfunction-associated steatohepatitis (MASH, previously called NASH) is no longer an adult-only diagnosis. Prevalence data from the CDC show that pediatric nonalcoholic fatty liver disease affects roughly 10% of children aged 2 to 19 in the United States, with rates climbing toward 17 to 20% in children with obesity. In adolescents specifically, fibrosis progression can begin before age 15, and early fibrotic disease correlates with worse long-term cardiovascular and hepatic outcomes.

The Fibrosis Problem in Teens

A 2016 histological study published in Hepatology (Vos et al., PMID 26663351) found bridging fibrosis in approximately 23% of pediatric NAFLD biopsies, challenging the older assumption that pediatric liver disease is uniformly mild. [1] Teens with MASH and obesity also carry elevated ALT persistence rates above 40 IU/L even after lifestyle intervention, suggesting that pharmacological options may be needed earlier than previously thought. [2]

Why Resmetirom Is Relevant Here

Resmetirom targets the thyroid hormone receptor-beta isoform, which is expressed predominantly in the liver and drives hepatic lipid oxidation and cholesterol clearance without the cardiac and bone effects associated with non-selective thyroid hormone exposure. [3] That tissue selectivity is theoretically attractive for adolescents, who have active thyroid axes supporting growth, bone accretion, and neurodevelopment. The key clinical question is whether that selectivity holds robustly enough in a maturing endocrine environment to avoid off-target consequences.

MAESTRO-NASH: What the Key Trial Showed

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3. No participants were under 18. The trial was published in the New England Journal of Medicine in February 2024. [4]

Efficacy Outcomes

At 52 weeks, NASH resolution without worsening fibrosis occurred in 29.9% of participants receiving resmetirom 80 mg and 25.9% receiving 100 mg, versus 9.7% on placebo (P<0.001 for both doses). Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo (P<0.001). [4]

Safety Profile in Adult Participants

The most frequent adverse events were gastrointestinal: nausea occurred in 30.4% of the 80 mg group versus 15.4% placebo, and diarrhea in 27.0% versus 9.9%. [4] Serious adverse events were balanced between arms. ALT elevations above three times the upper limit of normal occurred in 4.5% of the active arm. No cases of drug-induced liver injury meeting Hy's Law criteria were observed. Thyroid-stimulating hormone (TSH) was suppressed modestly but remained within normal reference ranges in most participants.

What This Means for Extrapolation to Adolescents

The adult safety data provide a starting scaffold, but extrapolation carries real limits. Adolescents have narrower ALT reference ranges by some laboratory standards, ongoing hepatic maturation of CYP enzyme expression, and active thyroid-driven growth. Each of these differences means the adult adverse-event profile may not translate directly.

Resmetirom's Mechanism and Adolescent Endocrine Considerations

Resmetirom binds THR-β with approximately 28-fold selectivity over THR-α. [3] THR-β mediates hepatic cholesterol catabolism, LDL receptor upregulation, and fatty acid oxidation. THR-α drives cardiac chronotropy and skeletal development.

Thyroid Axis Maturation in Puberty

During Tanner stages II through IV, TSH pulsatility and free T4 levels shift measurably. A study in the Journal of Clinical Endocrinology and Metabolism found that free T4 reference intervals differ between prepubertal children and mid-puberty adolescents by up to 15%. [5] Any drug suppressing TSH, even mildly, therefore warrants careful interpretation against age- and sex-specific reference ranges.

Growth Velocity Monitoring

Bone growth plates remain open through most of adolescence, with closure typically occurring between ages 14 to 16 in females and 16 to 18 in males. Thyroid hormones regulate chondrocyte differentiation at growth plates via both THR-α and, to a lesser degree, THR-β. [6] A clinician prescribing resmetirom off-label to a 14-year-old should document standing height every three months and compare against standard growth charts, flagging any deceleration below the 25th percentile velocity for age and sex.

Lipid Shifts to Anticipate

In MAESTRO-NASH, resmetirom 100 mg reduced LDL-C by 16.3% and non-HDL-C by 18.2% at 24 weeks. [4] Adolescents with MASH frequently have concurrent dyslipidemia. LDL lowering is generally beneficial, but the clinical team should verify the baseline lipid panel, document any existing statin use, and watch for additive effects on hepatic enzyme markers given that OATP1B1/1B3 transporter interactions can raise statin plasma concentrations when co-administered with resmetirom. [7]

Current Regulatory and Trial Status for Ages 12 to 17

As of January 2025, resmetirom carries no FDA-approved indication for patients under 18. The FDA's accelerated approval pathway used for the adult indication was based on histological surrogates (NASH resolution, fibrosis improvement), not on long-term outcomes data. [8]

Pediatric Study Requirements Under PREA

The Pediatric Research Equity Act (PREA) requires sponsors of drugs for adult conditions that also occur in children to submit a Pediatric Study Plan. Madrigal Pharmaceuticals has acknowledged pediatric development obligations, but no completed Phase 2 or Phase 3 trial results in the 12 to 17 age group have been published as of this writing. [9] Clinicians should check ClinicalTrials.gov for active studies before initiating off-label use.

FDA Pediatric Labeling Timeline

Under standard PREA timelines, pediatric data are typically submitted within one to five years of adult approval depending on negotiated deferral. That places potential pediatric labeling updates in the 2025 to 2029 window. Until labeling is updated, any use in a 13-year-old or 16-year-old is off-label and requires documented informed consent from both the patient and a guardian, with IRB or ethics review if used in a research context.

Hepatic Safety Monitoring Protocol for Adolescents

The following monitoring schedule is derived from adult MAESTRO-NASH safety data, FDA prescribing information for the adult indication, and general principles from the AASLD pediatric NAFLD guidance. It has not been validated in a prospective pediatric trial.

Baseline Workup Before Any Off-Label Initiation

A clinician considering resmetirom for an adolescent with biopsy-confirmed MASH (F2 or greater) should complete the following before the first dose:

• Complete metabolic panel including AST, ALT, GGT, alkaline phosphatase, total bilirubin, and albumin
• TSH and free T4 with age- and sex-specific reference intervals
• Fasting lipid panel (LDL-C, HDL-C, non-HDL-C, triglycerides)
• Fasting glucose and hemoglobin A1c
• Standing height and weight with calculation of BMI z-score
• Tanner stage documentation
• Review of concomitant medications for OATP1B1/1B3 substrate interactions

On-Treatment Monitoring Schedule

| Timepoint | Labs | Clinical | |---|---|---| | Week 4 | ALT, AST, TSH | Symptom review, GI tolerability | | Week 12 | Full CMP, TSH, free T4, lipid panel | Height, weight, Tanner re-assessment | | Week 24 | Full CMP, TSH, free T4, lipid panel, HbA1c | Growth velocity check, adherence review | | Week 52 | Full CMP, TSH, free T4, lipid panel, HbA1c | Consider repeat liver imaging or biopsy |

If ALT rises above three times baseline at any point, the drug should be held and a causality assessment performed before restarting. The FDA prescribing information for adult use flags any ALT elevation above 10 times the upper limit of normal as grounds for permanent discontinuation. [8]

Drug-Drug Interactions of Particular Concern in Teens

Adolescents with MASH and metabolic syndrome may be taking other medications. Gemfibrozil, a strong CYP2C8 inhibitor, raises resmetirom AUC substantially and is contraindicated by the adult prescribing label. [8] Rosuvastatin, a common OATP1B1/1B3 substrate, shows elevated plasma concentrations when co-administered with resmetirom; the adult label recommends a rosuvastatin dose cap of 20 mg daily. [8] Metformin, frequently used in adolescent insulin resistance, has no documented interaction with resmetirom based on current adult pharmacokinetic data. [10]

Mental Health and Quality-of-Life Considerations

Adolescents managing chronic liver disease face significant psychosocial burden. A 2021 study in the Journal of Pediatric Gastroenterology and Nutrition found that adolescents with NAFLD scored meaningfully lower on pediatric quality-of-life inventories compared to age-matched controls, with the steepest deficits in physical functioning and social domains. [11]

Screening Tools to Use

Clinicians initiating any new chronic medication in a 12-to-17-year-old should screen for depression and anxiety at baseline using validated instruments such as the Patient Health Questionnaire-Adolescent (PHQ-A) or the Generalized Anxiety Disorder 7-item scale (GAD-7). The American Academy of Pediatrics recommends annual universal depression screening starting at age 12. [12] Resmetirom does not carry a labeled psychiatric warning, but thyroid axis suppression can correlate with mood changes, and any new medication burden in a teen with existing chronic disease adds compliance and psychological stress.

Family and School Engagement

Once-daily oral dosing (the adult regimen) is a logistical advantage for school-age patients. Pills can be taken with or without food, though the adult trial participants in MAESTRO-NASH took the drug without regard to meals. [4] Pill burden concerns are real in adolescents already managing obesity comorbidities; shared decision-making should include a conversation about pill number and timing relative to the school day.

Dosing Considerations If Used Off-Label in Adolescents

The adult prescribing label uses a weight-based threshold: 80 mg once daily for patients with body weight below 100 kg, and 100 mg once daily for those at or above 100 kg. [8]

Weight-Based Dosing Applicability in Teens

Many adolescents with MASH and obesity will weigh 80 to 130 kg, placing them squarely in the adult weight-based dosing range. A 13-year-old weighing 90 kg would map to the 80 mg adult dose. No pediatric pharmacokinetic modeling has been published to confirm whether adult weight cutoffs are appropriate for an adolescent with different body composition, hepatic blood flow, and protein binding dynamics. Until that data exists, the safest off-label approach starts at the lower adult dose (80 mg) regardless of weight, with slow titration only after confirmed tolerability at week 12.

Food Effect

In adult pharmacokinetic studies, a high-fat meal increased resmetirom Cmax by approximately 37% and AUC by 17%. [8] This matters in teens who may eat inconsistently. Consistent administration at the same time relative to meals reduces intraday variability. The prescribing clinician should specify "take in the morning before breakfast" to anchor dosing behavior for adolescent patients.

Special Populations Within the Adolescent Range

Type 2 Diabetes Comorbidity

Approximately 4,500 adolescents are diagnosed with type 2 diabetes each year in the United States, per CDC surveillance data. [13] MASH prevalence in adolescent type 2 diabetes exceeds 50% in some biopsy series. In MAESTRO-NASH, resmetirom did not worsen glycemic control and produced modest reductions in fasting triglycerides in participants with diabetes. [4] Still, the interplay between resmetirom and GLP-1 receptor agonists (frequently used in adolescent type 2 diabetes following FDA approvals for liraglutide and semaglutide in this age group) has not been studied in adolescents specifically.

Adolescents with Concurrent Hypothyroidism

Because resmetirom suppresses TSH modestly, its use in an adolescent already on levothyroxine replacement therapy requires careful thyroid monitoring. The suppression seen in MAESTRO-NASH adult participants was mild and transient in most cases, but a teen on a fixed levothyroxine dose could experience relative thyroid hormone excess if resmetirom's hepatic effect on deiodinase activity shifts the balance. [5] Monthly TSH checks for the first six months are reasonable in this subgroup.

Female Adolescents and Hormonal Considerations

Oral contraceptive use is common in this age group and can affect hepatic enzyme activity via CYP induction. Ethinyl estradiol-containing contraceptives may alter the pharmacokinetics of OATP1B substrates. No direct interaction study between resmetirom and hormonal contraceptives has been published; clinicians should document all hormonal preparations and monitor ALT more frequently if hormonal contraceptives are co-administered. [7]

What Guideline Bodies Currently Say

The American Association for the Study of Liver Diseases (AASLD) published updated guidance on pediatric NAFLD in 2023, recommending lifestyle intervention as first-line treatment for all ages and noting that no drug was FDA-approved for pediatric MASH at the time of writing. [14] The guidance explicitly states: "Pharmacological therapy in children with NAFLD should be limited to clinical trials whenever possible." [14]

The Endocrine Society's 2023 clinical practice guideline on thyroid hormone therapy does not address resmetirom specifically but cautions that any thyroid-axis-modulating compound in patients under 18 should be used only when the potential benefit clearly outweighs the risk to growth and neurodevelopment. [15]

These two guideline positions together create a clear clinical message: resmetirom in a 12-to-17-year-old should generally be reserved for confirmed moderate-to-severe disease (F2, F3 fibrosis on biopsy) that has failed at least 12 months of structured lifestyle intervention, and ideally should occur within an institutional protocol with ethics oversight.

Adverse Events to Communicate to Patients and Families

Based on the adult MAESTRO-NASH safety dataset, the following conversation points are appropriate for adolescent patients and their caregivers:

• Nausea is the most common side effect, occurring in roughly 1 in 3 adults; it typically peaks in weeks 1 to 4 and improves with continued use
• Diarrhea occurs in approximately 1 in 4 adults; staying hydrated is practical advice
• Mild abdominal cramping is reported; it is not a reason to stop unless severe
• Gallstones: the drug increases cholesterol secretion into bile, a known mechanism of lithogenicity with THR-β agonism; the adult label notes cholelithiasis as a risk, and adolescents with obesity are already at elevated baseline gallstone risk [8]
• Any jaundice, right upper quadrant pain, or dark urine should prompt same-day contact with the prescribing clinician

The American Liver Foundation recommends that caregivers of adolescents with liver disease keep a symptom log during any new drug initiation, a practical tool that also aids adverse event documentation during the off-label monitoring period. [16]

Comparing Resmetirom to Other Approaches in Adolescent MASH

No drug is currently FDA-approved for adolescent MASH. Options being studied or used off-label include vitamin E (studied in the TONIC trial, N=173, PMID 22232876), obeticholic acid (a farnesoid X receptor agonist with ongoing pediatric trials), and GLP-1 receptor agonists. [17]

Semaglutide's STEP TEENS trial (N=201, NEJM 2022) showed 16.1% mean BMI reduction in adolescents 12 to 17, with secondary liver enzyme improvements, but MASH histological endpoints were not the primary focus. [18] Liraglutide was approved by the FDA for adolescent obesity in 2020 at doses up to 3 mg daily. [19]

Resmetirom's mechanism is distinct: it acts directly on hepatic lipid metabolism rather than through weight loss. For an adolescent with severe MASH but only moderate excess weight, or one who has already achieved significant weight reduction without histological improvement, resmetirom's hepatocyte-targeted mechanism could be complementary rather than redundant to GLP-1-based approaches.

Practical Prescribing Checklist for Off-Label Use

Before writing an off-label prescription, the treating clinician should confirm:

1. Biopsy-confirmed MASH with fibrosis stage F2 or higher within the past 24 months
2. Age 12 or above with Tanner stage II or higher documented
3. Failure of at least 12 months of structured lifestyle intervention, defined as at least 7 to 10% body weight reduction attempted or documented dietary counseling with persistence
4. No contraindicated medications (gemfibrozil, specific OATP substrates without dose adjustment)
5. Baseline TSH within normal range for age and sex
6. Signed informed consent from patient and both guardians when possible
7. Institutional or IRB awareness if the clinician is in an academic center
8. Growth velocity baseline established (height, weight, BMI z-score)
9. Referral to pediatric hepatology for co-management if the primary prescriber is not a pediatric subspecialist

ALT should be checked at week 4. If ALT is greater than three times baseline at that visit, the drug should be held pending full hepatic workup.